An observational study in NAFLD and Type 2 Diabetes, sponsored by Central Hospital, Nancy, France. Status unknown at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-07-30.
Sponsored by Central Hospital, Nancy, France · Observational
Non Alcoholic Fatty Liver Disease (NAFLD) is an emergent disease worldwide, and soon the leading cause of hepatic transplant in the USA. Among this high number of patients, the current challenge is to detect or even predict patients at risk of inflammation (Non Alcoholic or Steatohepatitis or NASH) and end-stage fibrosis, which are the best predictors of liver-related mortality.
Visceral obesity is intimately associated with metabolic disease and adverse health outcomes, such as diabetes, and NAFLD. It has been demonstrated that visceral adipose tissue-linked inflammation was a risk factor of stroke, myocardial infarction, and others metabolic-related complications.
The aim of this study was to evaluate the association of the quantity and percentage of Visceral Adipose Tissue by Dual X-Ray Absorptiometry and liver stiffness by Fibroscan in patients with type 2 diabetes, and other predictors of fibrosis such as FIB-4 and Fibrotest. We retrospectively collected the data of all the diabetic patients who had undergone a DEXA and a Fibroscan between January 1st, 2014 and Decembre 31th, 2019, in the Universitary Hospital of Nancy, France.
10,925 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.
This study's planned enrollment of 86 is below the median of 233 across 2,220 observational studies indexed under Diabetes Mellitus.
Browse Diabetes Mellitus studies →Central Hospital, Nancy, France is the lead sponsor of 778 studies on the registry; 183 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All the patients with type 2 diabetes, followed and Universitary Hospital of Nancy, France, who had undergone a DEXA and a VCTE examination during their care path, in less than a year apart, between 2014 and 2019.
Exclusion Criteria:
All the patients with type 2 diabetes followed at Universitary Hospital of Nancy who had undergone a DEXA and a Fibroscan between 2014 and 2019.
Association between quantity of Visceral adipose Tissu and Liver Stiffness
Visceral adipose tissu in grams mesured by DEXA, and Liver stiffness in kiloPascal mesured par Vibration-Controlled Transient Elastography
Time frame: July to September 2020
Association between percentage of Visceral adipose Tissu and Liver Stiffness
Visceral adipose tissu in percentage on total fat mass mesured by DEXA, and Liver stiffness in kiloPascal mesured par Vibration-Controlled Transient Elastography
Time frame: July to September 2020
Association between quantity of Visceral adipose Tissue and histologic Fibrosis
Visceral adipose tissu in grams mesured by DEXA, and histologic fibrosis determined on hepatic biopsy.
Time frame: July to September 2020
Association between percentage of Visceral adipose Tissue and histologic Fibrosis
Visceral adipose tissu percentage on total fat mass mesured by DEXA, and histologic fibrosis determined on hepatic biopsy.
Time frame: July to September 2020
Determine the diagnostic performances of quantity of Visceral adipose Tissue for histologic fibrosis diagnosis.
Visceral adipose tissu in grams mesured by DEXA, and histologic fibrosis determined on hepatic biopsy.
Time frame: July to September 2020
Determine the diagnostic performances of percentage of Visceral adipose Tissue for histologic fibrosis diagnosis.
Visceral adipose tissu percentage on total fat mass mesured by DEXA, and histologic fibrosis determined on hepatic biopsy.
Time frame: July to September 2020
Determine the diagnostic performances of different biologic markers for histologic fibrosis diagnosis.
Histologic fibrosis determined on hepatic biopsy.
Time frame: July to September 2020
Build an algorithm with Visceral adipose Tissue mesured and biological markers to predict fibrosis.
Prediction algorithm for hepatic fibrosis based on different markers
Time frame: July to September 2020
Plan to share: Undecided
No publications or documents are linked to this record.
This study is status unknown, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Central Hospital, Nancy, France